Inhibition of gastric secretion by exogenous secretin and cholecystokinin in normals and duodenal ulcer patients.
The inhibitory effect of combined secretin (0.5 and 1.0 clin. unit/kg b.w./hour) and cholecystokinin (0.5 and 1.0 IDU/kg b.w./hour on the pentagastrin-stimulated (0.15--1.0 and 6.0 ug/kg b.w./hour) gastric secretion was investigated in twelve volunteers and in twelve duodenal ulcer patients. Regardless of the dose level no difference was found between normals and duodenal ulcer patients, indicating that a decreased sensitivity to secretin and cholecystokinin is not a pathogenetic factor for the development of duodenal ulcer.
D000328:Adult; D002766:Cholecystokinin; D004381:Duodenal Ulcer / Q000503:physiopathology*; D005260:Female; D005750:Gastric Juice / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin / Q000494:pharmacology; D012633:Secretin; D012636:Secretory Rate / Q000187:drug effects
D012633:Secretin; D002766:Cholecystokinin; D010418:Pentagastrin